MELANOMA STAGE IV

This study is for people with high-risk melanoma who have had surgery to remove their cancer. It uses a blood test to find tiny bits of tumor DNA that might be left behind. Participants will receive either a standard immunotherapy or a combination of two immunotherapy drugs to se…

This early-phase trial tests a new treatment called VET3-TGI, a virus designed to infect and kill cancer cells. It is given alone or with an immunotherapy drug (atezolizumab) to about 60 adults with advanced solid tumors that have not responded to standard treatments. The main go…

This study tests a new treatment for people with advanced cancers that have spread and express a protein called NY-ESO-1. Patients receive a single infusion of their own immune cells that have been genetically modified to recognize and attack cancer cells. The goal is to see if t…

This study tests whether combining two drugs—cyclophosphamide and pembrolizumab—can shrink tumors in people with advanced melanoma that no longer responds to standard immunotherapy. About 14 adults with stage III or IV melanoma will receive the combination. The goal is to see if …

This study tests a new treatment called [212Pb]VMT01, which delivers targeted radiation directly to melanoma cells. It is for people with advanced melanoma that has not responded to prior treatments. The study will see if this therapy is safe and effective when used alone or with…

This study tests whether giving immunotherapy before and after surgery helps people with advanced melanoma (stage III or IV). About 90 adults will receive treatment based on their tumor's unique markers. The goal is to see if this approach leads to a major or complete response in…

This study looks at whether adding targeted radiation to the brain (stereotactic radiotherapy) to standard immunotherapy drugs (ipilimumab and nivolumab) helps people with melanoma that has spread to the brain. About 218 adults with stage IV melanoma and untreated brain tumors wi…

This early-stage trial tests an experimental pill, GIM-531, in people with advanced solid tumors (including stage IV melanoma) that have stopped responding to standard treatments. The drug works by blocking certain immune cells that protect tumors, potentially helping the body fi…

This study tests whether combining two drugs, binimetinib and imatinib, can shrink tumors in people with advanced KIT-mutant melanoma that cannot be surgically removed. About 25 participants with stage III or IV melanoma will receive the drug combination. The goal is to see how m…

This study looks at whether giving extra treatment after surgery can lower the chance of melanoma coming back in people with advanced stage III or IV melanoma that has a BRAF V600 mutation. About 50 adults will receive a combination of two drugs (encorafenib and binimetinib) befo…

This study is for people with advanced melanoma (stage III or IV that cannot be removed by surgery) whose cancer has stopped responding to standard immunotherapy drugs like nivolumab or pembrolizumab. The trial tests a new sequence of three drugs: high-dose interleukin-2 (IL2) pl…

This study follows 40 people who received Miltenyi CAR T cell therapy at least one year ago. Researchers will track side effects, blood cell counts, growth, and overall health over time. The goal is to understand the long-term safety of these treatments.

This study looks at how beta-glucan, a natural fiber from yeast or mushrooms, affects the immune system in people with stage III or IV melanoma who are already taking the immunotherapy drug pembrolizumab. Researchers will measure changes in immune cells from blood samples. The go…

This study looks at whether combining PET/CT scans with a special blood test (ctDNA) can help doctors predict which patients with advanced melanoma will respond to immunotherapy and who might have side effects. About 24 adults with stage III or IV melanoma will be followed for ab…